Wiser Advisor Group LLC Sells 265 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wiser Advisor Group LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 53.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 230 shares of the medical research company’s stock after selling 265 shares during the period. Wiser Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $142,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Silvercrest Asset Management Group LLC raised its position in Thermo Fisher Scientific by 2.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 45,630 shares of the medical research company’s stock worth $26,521,000 after purchasing an additional 1,053 shares in the last quarter. Waverly Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 7.1% in the 1st quarter. Waverly Advisors LLC now owns 2,386 shares of the medical research company’s stock worth $1,387,000 after buying an additional 158 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $11,657,000. Industrial Alliance Investment Management Inc. raised its stake in Thermo Fisher Scientific by 2.4% during the first quarter. Industrial Alliance Investment Management Inc. now owns 853 shares of the medical research company’s stock worth $496,000 after acquiring an additional 20 shares in the last quarter. Finally, In Depth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 2.8% in the 1st quarter. In Depth Partners LLC now owns 13,262 shares of the medical research company’s stock valued at $7,708,000 after purchasing an additional 356 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This trade represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $1.63 during mid-day trading on Monday, reaching $514.89. The company’s stock had a trading volume of 202,037 shares, compared to its average volume of 1,489,582. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The business has a 50-day simple moving average of $575.70 and a two-hundred day simple moving average of $580.20. Thermo Fisher Scientific Inc. has a 1-year low of $480.57 and a 1-year high of $627.88. The stock has a market cap of $196.95 billion, a P/E ratio of 32.18, a PEG ratio of 3.39 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the prior year, the business earned $5.69 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TMO shares. Bank of America increased their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Evercore ISI decreased their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.